Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Fish and Richardson
Harvard Business School
McKinsey
Merck
Chinese Patent Office
Mallinckrodt
Medtronic

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,998,953

« Back to Dashboard

Summary for Patent: 7,998,953
Title:Use of inhibitors of the renin-angiotensin system
Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
Inventor(s): Montgomery; Hugh Edward (London, GB), Martin; John Francis (London, GB), Erusalimsky; Jorge Daniel (London, GB)
Assignee: Ark Therapeutics Group, p.l.c. (London, GB)
Application Number:11/119,181
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,998,953

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-002 Nov 10, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,998,953

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9722026.3Oct 17, 1997
United Kingdom9810855.8May 20, 1998

Non-Orange Book US Patents Family Members for Patent 7,998,953

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,071,183 Use of inhibitors of the renin-angiotensin system ➤ Sign Up
8,604,070 Use of inhibitors of the renin-angiotensin system ➤ Sign Up
8,003,679 Use of inhibitors of the renin-angiotensin system ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Baxter
Harvard Business School
AstraZeneca
Farmers Insurance
Dow
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.